Liu J, Miyakawa H, Liu J H, Marumo F, Sato C
Second Department of Internal Medicine, Faculty of Medicine, Tokyo Medical and Dental University, Japan.
Res Commun Mol Pathol Pharmacol. 1995 Mar;87(3):307-14.
Effects of verapamil, an calcium channel blocker, on hepatic glutathione were studied in vivo in the rat and in the perfused rat liver. An injection of verapamil at a dose of 15 mg/kg body weight but not at 5 mg/kg significantly decreased hepatic glutathione contents in both fed and fasted animals 6 h after the injection. The administration of verapamil at a dose of 10 mg/kg twice a day for a week brought a significant decrease in hepatic glutathione contents and a significant increase in plasma glutathione levels. In the perfused rat liver, sinusoidal glutathione efflux was significantly increased when verapamil was added to the perfusion medium in a concentration of 20 microM. These data indicate that verapamil increases glutathione efflux from the liver and that calcium mobilization may be concerned in glutathione efflux in vivo.
在大鼠体内及灌注的大鼠肝脏中研究了钙通道阻滞剂维拉帕米对肝脏谷胱甘肽的影响。注射剂量为15mg/kg体重而非5mg/kg的维拉帕米，可使喂食和禁食动物在注射后6小时肝脏谷胱甘肽含量显著降低。每天两次给予剂量为10mg/kg的维拉帕米，持续一周，可使肝脏谷胱甘肽含量显著降低，血浆谷胱甘肽水平显著升高。在灌注的大鼠肝脏中，当向灌注培养基中加入浓度为20μM的维拉帕米时，肝窦谷胱甘肽外流量显著增加。这些数据表明，维拉帕米可增加肝脏谷胱甘肽外流量，且钙动员可能与体内谷胱甘肽外流量有关。
